Practical algorithm to inform clinical decision‐making in the topical treatment of atopic dermatitis

Luger, Thomas A.; Adaskevich, Uladzimir P.; Anfilova, Maryna; Dou, Xia; Мурашкин, Н. Н.; Namazova-Baranova, Leyla; Nitochko, Oleg; Reda, Ahmed; Sviatenko, Tetiana; Tamay, Zeynep; Tawara, Mohammad; Вишнева, Е.А.; Возіанова, С. В.; Wang, Hua; Zhao, Zuotao

doi:10.1111/1346-8138.15921

Cited by 7 publications

(3 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…6,77 A recently published algorithm to inform clinical decision-making recommends regular use of emollients for early AD control. 78 However, the European guidelines note that direct sole use of emollients on inflamed skin is poorly tolerated, and so induction of remission with TCS or TCI is required before application of the emollient. 6 For long-term AD management, an alternative to TCS is required; 79 prolonged use of TCS can cause skin atrophy, barrier impairment, increased infection risk, and tachyphylaxis.…”

Section: Ad Topical Treatment Approaches: Guidelines and Supporting E...mentioning

confidence: 99%

See 1 more Smart Citation

The Role of a Novel Generation of Emollients, ‘Emollients Plus’, in Atopic Dermatitis

Araviiskaia¹,

Pincelli²,

Sparavigna³

et al. 2022

CCID

Self Cite

View full text Add to dashboard Cite

Emollients are the mainstay maintenance treatment for atopic dermatitis (AD). A novel generation of emollients, ‘emollients plus’, containing active, non-medicated substances, has softened the distinction between emollients and topical drugs. A literature search for selected key words was performed using PubMed. Additional papers were identified based on author expertise. Whilst the inclusion of five components of an ideal emollient has been proposed, no such consensus exists for emollients plus and they can vary markedly in their composition and modes of action for AD treatment. This could have a profound effect on their clinical efficacy. The efficacy of emollients plus in restoring and maintaining skin barrier function has been demonstrated on multiple levels, with evidence reported for their effects on the physical and biochemical, microbial, immunological, and neurosensory barriers. When selecting an appropriate AD treatment approach, the safety profiles of the available topical therapies must be carefully considered. There are several proposed treatment approaches for AD, including preventive, proactive, intermittent, and synergistic approaches. Emollients plus may be effective not only as maintenance therapy for AD, but also when used synergistically with anti-inflammatory pharmacological therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Ad Topical Treatment Approaches: Guidelines and Supporting E...mentioning

confidence: 99%

The Role of a Novel Generation of Emollients, ‘Emollients Plus’, in Atopic Dermatitis

Araviiskaia¹,

Pincelli²,

Sparavigna³

et al. 2022

CCID

Self Cite

View full text Add to dashboard Cite

show abstract

“…Frequently the onset of AD occurs in childhood, and in some cases may become a chronic lifelong disease. The prevalence of the disease among the child population reaches 20%, among the adult population about 3% worldwide [7].…”

Section: Introductionmentioning

confidence: 99%

Innate immune factor gene expression profiles in patients with atopic dermatitis

Bystritskaia,

Murashkin,

Olisova

et al. 2023

Med. immunol.

View full text Add to dashboard Cite

Atopic dermatitis is a multifactorial genetically determined inflammatory skin disease characterized by itching, chronically relapsing dermatitis, age-related features of localization and morphology of lesions. The pathogenesis of atopic dermatitis is complex and includes epigenetic alterations, involved in the genomic adaptation, immune response reactions and dysfunction of the epithelial barrier that together trigger the development of atopic dermatitis. The aim of this study is to detect the expression level for IL4, IL13, IL33, TLR2, TLR9 genes in the biological materials of atopic patients.The targeted genes for further expression evaluation were selected according to our previous findings on genome-wide methylation study. We detected the cascades with the differentially methylated genes that are most likely to take place in atopic dermatitis. Thus, we investigated expression levels for the IL4, IL13, IL33, TLR2, TLR9 genes in the skin, peripheral blood mononuclear cells and whole blood cells using RT-PCR on 55 pediatric patients and 26 healthy volunteers, and on 50 adult patients. Statistical analysis was performed with the use of Kruskal-Wallis H test and Mann-Whitney U test. Targeted expression analysis revealed that in the skin samples the expression of TLR9 and IL4 was 12 times significantly lower (p < 0.0001, p < 0.0005) in the lesional skin; and there was a 6-fold decrease in case of TLR2 (p < 0.01). The results for blood mononuclear cells differed and expression levels for most of the assessed targets were significantly higher before treatment. We have also found out that those differences were strongly pronounced especially in an elder age group (12-18 y.o.). Studying the IL33 gene expression in the whole blood samples of adults revealed that its level was significantly higher in case of patients with moderate form of AD. Besides, we concluded that locally in the affected skin inflammatory immune response may dominate; in the mononuclear cells Th2 immune response apparently takes place. New insights on immunological markers and links among them may shed a light on atopic dermatitis pathogenic mechanisms. The detected molecules could play role as potential therapeutic targets and form a management approach for patients with atopic dermatitis.

show abstract

Periocular Skin Lesions and Eyelid Tumours

Daniel,

Esmaeli,

Beaconsfield

2024

Oculoplastic, Lacrimal and Orbital Surgery

View full text Add to dashboard Cite

Practical algorithm to inform clinical decision‐making in the topical treatment of atopic dermatitis

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 7 publications

References 110 publications

The Role of a Novel Generation of Emollients, ‘Emollients Plus’, in Atopic Dermatitis

The Role of a Novel Generation of Emollients, ‘Emollients Plus’, in Atopic Dermatitis

Innate immune factor gene expression profiles in patients with atopic dermatitis

Periocular Skin Lesions and Eyelid Tumours

Contact Info

Product

Resources

About